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Abstract
Background: The potential dynamics of cognitive impairment in schizophrenia is discussed in the literature of the
field. Recent publications suggest modest changes in level of cognitive impairment after first psychotic episode.
Present article attempts to explore cognitive differences between patients and controls across age groups and
differences between age groups in clinical group.
Methods: One hundred and twenty-eight hospitalized patients with schizophrenia (64 women and 64 men) and 68
individuals from the control group (32 women and 32 men) aged 18–55 years were examined. The patients were
divided into age groups (18–25, 26–35, 36–45, 46–55). Both groups were examined using Wisconsin Card Sorting
Test, Rey Auditory Verbal Learning Test, Rey Osterrieth Complex Figure Test, Trail Making Test (A and B), Stroop Test,
verbal fluency test and Wechsler digit span.
Results: Patients with schizophrenia obtained significantly lower scores versus the control group in regard to all
the measured cognitive functions (Mann–Whitney U; p < 0.05. Most deficits were present in all age groups,
however, statistically important impairment in executive functions (WCST) were present only in “older” groups.
Conclusions: Patients with schizophrenia obtained less favourable results than the control group in all age groups.
Deficits regarding executive functions do not seem to be at a significant level among the youngest group, whereas
they are more noticeable in the group of 46–55-year-olds. Executive functions are significantly lowered in the group
aged 36–45 in comparison to the “younger” groups. The level of cognitive functions shows a mild exacerbation in
connection with age, whereas cognitive rigidity proved to be related to the number of years spent without hospital
treatment.
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Background
In his pioneering research, Bleuler already noticed that
the essence of schizophrenia are not hallucinations or
delusions but the so-called axial symptoms that signifi-
cantly affect the global functioning of patients. In her
works, Andreasen [1] presented a neo-Bleulerian model,
describing schizophrenia as a neurodevelopmental dis-
order with the occurrence of primary cognitive deficits
corresponding to "axial" symptoms [1–4]. The neurode-
velopmental irregularities present in schizophrenia may
arise from the incorrect formation of large-scale neural
networks, for example at the axonal level, but in most
cases, the dysfunction occurs at the level of sending and
receiving information via synapses or dendrites [5]. A
consequence of these irregularities is the phenomenon
of cognitive dysmetria associated with impaired coordin-
ation between thinking and action, leading to the distortion
of such cognitive processes as memory, attention focus,
language, emotional intelligence and awareness [2, 6].
Currently two main theories are presented regarding
the dynamics of the disease process in schizophrenia.
The first theory assumes a gradual stabilization of the
mental condition in a relatively short period of time (2–5
years) from the onset, or the transition to the stationary
form of schizophrenia [7]. This hypothesis provides for the
possibility of a slight improvement in the general psycho-
pathology and cognitive impairments. The second theory
considers a gradual build-up of impairment beginning in
the prodromal phase where the cognitive dysfunctions,
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discrete negative symptoms and behaviour disorders are
visible through the acute phase of the disease with the oc-
currence of severe positive symptoms. In this theory, the
subsequent phases of the disease include the occurrence of
periods of remission and exacerbation with progressively
aggravated course, leading to the final phase of schizophre-
nia with predominantly negative symptoms and intensified
cognitive impairment [8, 9]. This hypothesis would there-
fore assume the progression of cognitive deficits associated
with time from the onset of the first symptoms and age.
The cognitive impairments present in schizophrenia
most frequently cited in the literature include impair-
ments of working memory, executive functions, verbal
fluency, attention, and disturbances in the selection and
processing of information [10–12]. It is believed that this
type of disorders are present in 85 % of the patients and
are negatively correlated with psychosocial functioning
and cooperation in therapy [10]. The research most
often emphasizes their specific and selective character in
schizophrenia [13–15] and does not confirm the increase
in cognitive deficits during the course of the disease, but
rather their stability and independence from the clinical
picture [7]. Numerous previous and contemporary stud-
ies proved the occurrence of cognitive disorders many
years before the onset of the disease, frequently even in
childhood [16–20]. The occurrence of cognitive disor-
ders confirmed with neuropsychological tests is a more
specific marker of early schizophrenia, than for example,
diagnostics by means of structural MRI (sMRI) [21].
The occurrence of cognitive deficits in schizophrenia
may be explained by the glutamate hypothesis. Cognitive
disorders can be a consequence of the neurotoxic activ-
ity of the psychosis and the external factors [8, 9, 22]
and some researchers believe that the progressive
process of neuronal degeneration and the associated
increase in "residual" symptoms may be the result of ex-
cessive glutamatergic transmission. According to them,
in the context of excessive excitation of the glutamater-
gic transmission a toxic neurodegenerative excitation
could occur, in which the NMDA receptor would be
involved. In theory, as a result of the initiated patho-
logical process this normal neuronal excitation process
would lead to a random toxic excitation that would in
turn lead to neuronal damage due to slow neurodegener-
ation resulting from the opening of the calcium chan-
nels, secondary activation of the intracellular enzymes,
and generation of free radicals toxic to cell membranes
and intracellular structures [8, 9, 23]. Consequently, this
would lead to the overlapping of primary cognitive defi-
cits with secondary cognitive disorders, associated with
the phenomenon of excitotoxicity and neurodegenera-
tion. The phenomenon of neurodegeneration is reflected
in the neuroimaging studies of patients with long-term
course of schizophrenia. In the group of patients with
schizophrenia there is a decline in the volume of the
gray matter and the white matter, which is associated
with age exacerbations. In case of gray matter an overall
reduction of its volume is observed with particular
intensity in the frontal cortex and the thalamus area
whereas white matter atrophic changes relate mainly to
the frontal, temporal and parietal regions. The widening
of lateral ventricles and the enlargement of fluid spaces
in the frontal, temporal and parietal regions were also
observed in longitudinal brain MRI studies [24]. The
above-mentioned changes were correlated with cognitive
impairment, but had little impact on other clinical pa-
rameters [16, 24–26].
At the same time, the results of some meta-analyses
show a similar role being played by factors other than
the course of the disease, such as the influence of medi-
cations or overuse of psychoactive substances. These
meta-analyses suggest that there is no clear proof for the
neurodegenerative nature of schizophrenia [27]. At the
same time, a study combining longitudinal and cross-
sectional methodologies shows a similar level of cogni-
tive disorders in patients after their first schizophrenia
episode to those with an established clinical picture of
the disease [27]. Individual studies also show the pres-
ence of other factors, such as metabolic syndrome, low-
ered BDNF, improper diet, low level of physical activity
or stigma [28]. The reversibility of processes causing
lowered levels of functioning is also shown in research
on rehabilitation, both in terms of symptoms and the so-
cial aspect, where patients experience tangible benefits
when cognitive remediation training is included as a part
of comprehensive psychiatric rehabilitation [29–31].
Complex rehabilitation proved to have an impact on glo-
bal functioning and global cognitive improvement was a
mediator for improvements in functional outcomes [30].
Many patients can then recover or benefit from proper
rehabilitation.
Therefore, it is important to clarify whether the cogni-
tive disorders in schizophrenia exacerbation are static or
progressive with the duration of the disease and whether
they are associated with the patient's age or other factors
(duration of the disease, medication, number of hospital-
izations, years of education, difference between years
from onset and years form 1st hospitalization). Variable
intensity relationships can be expected between cogni-
tive functions and aforementioned factors. This study
pertains to a conducted correlation analysis between the
cognitive tests results and aforementioned factors. It is
expected that statistically significant differences occur
between clinical and control groups, whereas the
strength and number of those differences should grow
along with age in the individual age groups. The main
objective of the study is to analyse the differences in the
number and type of cognitive functions which are
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lowered in case of people with schizophrenia with regard
to the control group for individual age groups. It can be
expected that the lowering of cognitive functions will be
visible in all age groups, although it is difficult to predict
in which areas it will be particularly noticeable.
The present study aimed to determine the seriousness
of the dysfunctions suffered by patients with schizophre-
nia, whether these “deficits” [3] (in comparison to con-
trols) are global vs. selective, or whether they are “more
visible” across age groups.
Methods
Examined groups
The study was conducted one time in a group of 128
patients (64 W+ 64 M) aged 18–55 years, hospitalized
with a diagnosis of paranoid schizophrenia. The numbers
of patients in individual age groups are presented in
Table 1.
The diagnosis was made on the basis of DSM-IV-TR
criteria [27]. The control group consisted of 64 healthy
individuals (32 W + 32 M) matched for sex and age with
the clinical group. A minimum education threshold of
12 years was determined for both groups. Patients with
psychiatric co-morbidity, sight or hearing disorders,
movement disorders or chronic somatic illness were ex-
cluded from the study. All patients participating in the
study met the criteria for psychotic exacerbation mea-
sured using the PANSS scale [30].
In the studied group of 128 patients with schizophre-
nia the number of hospitalizations in the individual
groups (18–25, 26–35, 36–45, 46–55) increased with the
age of patients and the duration of the disease process.
The length of the current hospitalization did not differ
in a statistically significant manner in the individual age
groups and the mean was 6.5 weeks. The age and sex of
the examined patients was controlled. The mean time
that elapsed since the first hospitalization was 1.25 years
in the youngest age group and reached 14.31 years in
the oldest group (the mean for the entire group was
7.7 years). The mean time that elapsed from the onset of
these symptoms to the first hospitalization was deter-
mined on the basis of a thorough history taking oriented
towards the occurrence of increasing prodromal disor-
ders. In patients diagnosed with schizophrenia, who
participated in the study it was 1.4 years. More clinical
data is illustrated in Table 2.
Statistically significant differences between patients
and healthy individuals were revealed regarding: the level
of education, professional activity, remaining in stable
relationships and having children. All patients participat-
ing in the study met the criteria for psychotic exacerba-
tion. The mean total PANSS score was 78.4 (SD = 17.6)
points. The distribution of the mean scores in individual
age groups was as follows: 1) 84.34; 2) 75.28; 3) 73,84; 4)
80.06. The correlations of the PANSS results and the
neurocognitive tests were slight or weak in the whole
group of patients (N = 128). Only in the case of the G7
scale (PANSS)—motor retardation and the verbal part of
the Stroop test a moderately high negative correlation
occurred (−0.58). The relationship between the clinical
picture and neurocognitive variables was not confirmed
in the study. Patients in the examined age groups were
treated with both atypical and classical neuroleptics in
oral and depot forms. For statistical purposes, all doses
of medications administered to patients were converted
to chlorpromazine equivalents in accordance with the
applicable standards. The mean dose of the applied
treatment expressed as chlorpromazine equivalent was
660 mg and in the individual age groups (in ascending
order): 1) 493.04 mg; 2) 579.12 mg; 3) 446,38 mg; 4)
Table 1 The number of subjects in individual age groups
(clinical and control groups)








Table 2 Selected clinical and demographic data—patients with
schizophrenia
Age group
18–25 Education (years) M = 12,546 sd = 1,700
Children M = 0,000 sd = 0,000
Number of hospitalizations M = 2,187 sd = 1,635
Years from 1st hospitalization M = 1,250 sd = 1,736
Years from onset of disease M = 2,406 sd = 2,284
26–35 Education (years) M = 13,406 sd = 2,241
Children M = 0,218 sd = 0,6082
Number of hospitalizations M = 5,187 sd = 4,828
Years from 1st hospitalization M = 4,156 sd = 4,141
Years from onset of disease M = 5,046 sd = 4,028
36–45 Education (years) M = 12,312 sd = 2,292
Children M = 0,750 sd = 1,218
Number of hospitalizations M = 10,312 sd = 11,487
Years from 1st hospitalization M = 10,968 sd = 7,310
Years from onset of disease M = 12,562 sd = 7,052
46–55 Education (years) M = 12,375 sd = 2,075
Children M = 1,187 sd = 1,856
Number of hospitalizations M = 10,000 sd = 11,210
Years from 1st hospitalization M = 14,312 sd = 7,997
Years from onset of disease M = 16,645 sd = 7,918
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528,96 mg;. The maximum administered dose was
1633 mg and the minimum was 75 mg expressed as
chlorpromazine equivalent. Sixty-two percent of the ex-
amined patients received second-generation medications
and the most commonly administered neuroleptics were:
olanzapine, clozapine, risperidone, and perphenazine.
The mean total score of the MADRS scale for the whole
group of patients was 11.9 (SD = 8.9). The patients ob-
tained the highest score in the MADRS [32] scale in two
categories: subjective assessment of depression and diffi-
culties in focusing attention.
Applied methods
A demographic—descriptive questionnaire, PANSS scale
[30], MADRS scale, Wisconsin Card Sorting Test [33],
Rey Auditory Verbal Learning Test, Rey-Osterrieth
Complex Figure Test (ROCFT), TMT A [34], TMT B,
Wechsler digit span and a verbal fluency test were used
in the study.
PANSS (Positive and Negative Syndrome Scale) is a
method created 1987 to measure the level of symptoms
of schizophrenia, commonly used in studies on pharma-
cotherapy. MADRS (Montgomery-Asberg Depression
Rating Scale) is a scale for evaluation of the level of
depression, filled in by a clinician. Wisconsin Card
Sorting Test (WCST) is a neuropsychological test used
to measure executive functions, particularly mental flexi-
bility in light of changing stimuli. Rey Auditory Verbal
Learning Test (RAVLT) is used to measure the verbal
and lingual ability to learn (acquiring, storing and re-
trieving verbal material). Rey-Osterrieth Complex Figure
Test (ROCFT) is a method used to measure visual and
cognitive functions, as well as perceptual organisation.
Trail Making Test versions A and B (TMT A and TMT
B) are tests used to measure visual attention and task
switching. Wechsler Digit Span is a part of Wechsler's
battery used to measure rote memory, whereas the test
of fluency in terms of vocabulary measures the ability to
retrieve words from memory and update them.
The RAVLT test examination procedure consisted in
the examiner reading a series of 15 words (List A), from
which the participant was supposed to recall as many
words as possible. This procedure was repeated five
times to give the examined individual the opportunity of
learning the examination material. Subsequently a differ-
ent list (list B) was read once with the instruction to re-
member as many words as possible. Later, the examined
individual was asked to recall the words from list A from
memory. After a 30 min interval, the examined individ-
ual was asked to recall without prompting the words
from A list. The number of individual words in the
series A1-A5, in the list B, delayed recalls with and with-
out time interval were taken as the test performance
metrics. In the ROCFT test the examined individuals
were asked to copy a complex figure and then reproduce
it from memory after 3–5 min. The number of correctly
reproduced elements of the figure was adopted as the
performance metric. In TMT A and B, the time of the
correct performance of each part of the test was adopted
as the performance metric. In the test of verbal fluency,
the number of words recalled in 1 min was adopted as
the performance metric. In Wisconsin Card Sorting Test
the 64-card version was used, in which the examined
individual had to match cards according to one of three
possible criteria: color, geometric shape or number. In
the WCST study the number of correct answers, sum of
all errors committed, perseverative responses, persevera-
tive errors, other errors, conceptual responses, number
of attempts in the first category, sum of completed cat-
egories and the failure to maintain set were assessed.
The number of items read within 1 min was taken as
the performance metric of the Stroop test. The three
typical parts of the test were used and the coefficient of
interference was also calculated.
The Bioethics Committee of the Medical University of
Warsaw was informed about the methodology of the
study, procedure of consent, and approved its conduc-
tion. Patients have signed a consent to use their anon-
ymised figures obtained through diagnostic tests in
statistics required for this study. Anna Mosiołek deemed
patients able to consent, basing on legal criteria of in-
formed consent.
Statistics
The Mann–Whitney U test was used to determine the sig-
nificance of inter-group differences. Spearman's rank cor-
relation coefficient was used to measure the correlations
obtained in the study. Statsoft STATISTICA and SPSS
Statistics 18 software was used for statistical analyses. In
order to determine the level of significance of differences
the Mann–Whitney U nonparametric test was used,
whereas the determination of relationships’ strength be-
tween variables connected with the course of the disease
and the level of cognitive functions was calculated using
the Spearman's rank correlation coefficient.
Results
The relationships between the cognitive functions and
the demographic variables and variables associated with
the treatment process
A weak negative correlation between the years of
education and the dose of administered medications
(Rho = -0.177; p = 0.05) expressed as chlorpromazine
equivalent seems interesting, whereas there is no
correlation between the doses of medication and age.
Correlations presented in Tables 3-6 reflect mainly
negative associations between executive functions and
aging, and time from disease onset. Most of these
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correlations are weak. Weak relationships between the
performance of the WCST and difference between years
from onset and years from 1st hospitalization were also
found. Only rows and columns that contain significant
or interesting correlations are presented in the tables.
Similar relationships are found in the case of digit
span forward and digit span backwards tests, phonemic
fluency, Stroop test, RAVLT, ROCFT and TMT. Very
similar significant correlations (Spearman’s Rho values
0.24–0.31; p = 0.05) were detected between RAVLT test
score and age, and Time of Stroop interferention subtest
and age. Interestingly, the presented data didn’t reveal
connection between score in WCST and age or education
in the control group.
Cognitive functioning—intergroup comparisons
The analysis of the obtained data began with a comparison
of the clinical group versus the control group in regards
to all measured cognitive functions, as presented in
Table 7. Due to the unfulfilled requirements for the t test,
the nonparametric Mann–Whitney U test was used. It
was found that patients with schizophrenia obtained less
favourable score in all possible attempts in all the tests.
The Table 8 shows average results of all subtests used in
the study.
Significant differences were revealed between patients
with schizophrenia and controls in all the domains of
measured cognitive functions. The obtained results
allowed for conducting further analyses, with the aim to
compare the individual corresponding age groups to the
clinical group and the control group.
Comparison of corresponding age groups regarding
cognitive functions
For further analyses subtests considered key in the indi-
vidual tests were selected: the number of errors in
WCST (attention and working memory impairments),
number of perseverative errors in WCST (“on-line” pro-
cessing impairment), number of completed sequences in
WSCT (planning), RAVLT A7 delayed recall score (re-
trieval from memory), RAVLT recognition (ability to re-
member), main elements of ROCFT (visual memory),
TMT B (planning and set-shifting), Wechsler's digits span
forward (rote auditory memory), phonemic verbal fluency
and Stroop's interference (inhibitory control) (see Tables 8
and 9).
In Table 9 statistically significant differences were
highlighted with bold print. The significant results in the
Mann–Whitney U tests presented above can be read in
two ways. Analyzing the data by columns will illustrate
Table 3 Relationship between the variables associated with the course of disease and the test results—correlations (Spearman’s

























Age -,273a ,292a ,129 ,081 -,256a -,280a ,247a -,213b
Education (years) ,051 -,051 -,050 -,051 ,110 ,001 ,016 ,219b
Hospitalizations -,080 ,094 ,028 ,010 -,104 -,189b ,142 -,102
Time from 1st hospitalization -,182b ,211b ,055 ,043 -,202b -,225b ,199b -,182b
Time from onset of schizophrenia -,203b ,213b ,085 ,070 -,211b -,218b ,224b -,190b
Diffrerence between years from
onset and years from 1st
hospitalization
-,069 ,061 ,185b ,200b -,055 ,083 -,050 -,082
aCorrelation is significant at the 0.01 level (2-tailed)
bCorrelation is significant at the 0.05 level (2-tailed)
Table 4 Relationship between the variables associated with the course of disease and the test results—correlations (Spearman's















Age -,149 -,182b -,032 -,254a -,195b -,283a -,241a
Hospitalizations -,101 -,106 -,040 -,163 -,196b -,187b -,206b
Time from 1st
hospitalization
-,178b -,134 -,077 -,180b -,262a -,240a -,244a
Time from onset of
schizophrenia
-,193b -,116 -,039 -,211b -,218b -,247a -,246a
aCorrelation is significant at the 0.01 level (2-tailed)
bCorrelation is significant at the 0.05 level (2-tailed)
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which age groups demonstrate significant differences
with regard to specific cognitive functions Analyzing the
data by rows will illustrate the number of differences
within the various functions in an individual age group.
Raw scores were presented in Table 8.
The obtained results seem to suggest that subjects
with corresponding age groups differ significantly in
level of cognitive functioning. Individuals with schizophre-
nia aged 26–35 years start to have noticeable difficulties in
comparison to controls with correct performance in one
subtest of WCST, while patients from subsequent age
groups scored lower than controls in more subtests of
WCST. Interestingly, there were no significant differences
in WCST scores between patients and controls in the
youngest groups, however, raw scores suggest that execu-
tive functions can be lower in this group of patients.
Significance of the differences between contiguous age
groups of patients was analyzed. Patients aged 18–25
differed significantly from patients aged 26–35 only in
number of words read in Stoop A subtest. Groups 26–35
and 36–45 differed from each other by score in Stroop test,
TMT test, and number of retrieved elements in ROCFT
(p < 0,05). RAVLT Recognition was the only subtest that
differed the 36–45 and the 46–55 groups significantly
(p = 0043). In every comparison scores of “older”
groups were less favourable than “younger” groups.
In attempt to find potential sources of executive
impairment, correlations of WCST and other variables
were analyzed. Perseverative errors in WCST correlated
significantly with PANSS Disturbance of volition (0.22),
Sequences completed and conceptual level correlated
with PANSS Preoccupation scale (0.18). Similar power of
correlations was observed in relation of WCST Persever-
ative errors and number of months of 1st untreated
psychosis (0.20).
Discussion
The neurocognitive tests results obtained in the present
study confirm previous reports that schizophrenia is a
disease in which generalized cognitive dysfunctions
occur [35–37]. Cognitive disorders observed in patients
with schizophrenia occurred in the majority of measured
cognitive domains and the number of deficits were
present across all age groups.
In patients with schizophrenia cognitive disorders (in
comparison to their specific age group) were present in
each of the basic cognitive domains such as verbal-
linguistic learning, visual memory, inhibitory control,
planning, set-shifting, rote memory, auditory memory,
working memory and verbal fluency. Cognitive disorders
appeared in patients in all age groups (18–55 years) and
the patients performed the tasks less efficiently than
healthy individuals. The obtained results confirm the re-
sults of other studies covering multiple domains of cog-
nitive functioning [16, 37, 38].
The results of the present study may be seen as partly
similar to other researchers’ conclusions. In several longi-
tudinal studies [28] the progression of neuropsychological
Table 5 Relationship between the variables associated with the course of disease and the test results—correlations (Spearman’s
rank correlation coefficient)—patients with schizophrenia
RAVLT A1-A5 RAVLT A6 RAVLT A7 RAVLT B RAVLT Recognition
Age -,270a -,273a -,227b -,206b -,332a
Children -,086 -,046 -,030 -,185b -,070
Hospitalizations -,182b -,215b -,123 -,161 -,091
Time from 1st hospitalization -,308a -,332a -,243a -,198b -,229b
Time from onset of schizophrenia -,310a -,331a -,253a -,195b -,298a
aCorrelation is significant at the 0.01 level (2-tailed)
bCorrelation is significant at the 0.05 level (2-tailed)
Table 6 Relationship between the variables associated with the course of disease and the test results—correlations (Spearman’s
rank correlation coefficient)—patients with schizophrenia
ROCFT similarity ROCFT main elements Time TMT A Time TMT B
Age -,218b -,194b ,391a ,350a
Education (years) ,029 ,080 -,195b -,180b
Children -,038 -,005 ,206b ,080
Hospitalizations -,121 -,099 ,201b ,177b
Time from 1st hospitalization -,200b -,176b ,326a ,303a
Time from onset of schizophrenia -,197b -,183b ,342a ,308a
aCorrelation is significant at the 0.01 level (2-tailed)
bCorrelation is significant at the 0.05 level (2-tailed)
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disorders associated with age was not confirmed. Present
study suggests that patients with schizophrenia performed
on the tasks significantly worse than healthy individuals,
which suggests occurrence of cognitive deficits in early
course of the disease, while raw scores indicate their rela-
tive stability across the age group. In terms of executive
functions, other studies show their initial deficits before
the disease onset, while they subsequently reach a stable
level and later rapidly drop during in older age [39, 40].
The data collected for this article confirms that pattern.
The youngest groups show slight, negligible differences,
which become significant and stable as people in these
groups age.
In one other research the deterioration of the results
obtained in neurocognitive tests in patients aged 40–
80 was observed mainly in the domains of verbal
learning and processing speed [41]. In present study
many more deficits were observed in every measured
cognitive domains. The fact is consistent with other
study that confirm faster cognitive deterioration in
older patients with schizophrenia than in the control
group [39, 40].
On the basis of the obtained data one may conclude
that older patients with schizophrenia have relatively
greater levels of cognitive impairment associated with
age versus healthy individuals [42]. However, other
authors claim that these effect is not connected with
deterioration, but can rather be explained by poor en-
gagement in care, access to treatment, treatment re-
sponse or cumulative influence of substance abuse,
deficits in cognition, and other psychosocial factors [43].
Collected data suggests that differences between clinical
group and controls in executive functions of working mem-
ory and attention (errors in WCST) can be “more visible”
in group of 26–35 years old, “later” than other cognitive
disturbances that are present in all age groups, and there-
fore can be more “primary” than other. The next executive
impairment (in comparison to controls) that is “more vis-
ible” in subsequent age group is “on-line” processing (per-
severative errors) and planning (completed sequences).
Table 7 Level of the individual cognitive functions—differences between patients with schizophrenia (N = 128) versus the control
group (N = 68)
Scale Schizophrenia (N = 128) Controls (N = 68) Test of difference Sign.
M sd M sd Test U p
WSCT correct answers 26,61 11,318 35,76 9,244 2019,5 0,000
WSCT total errors 36,37 11,821 27,37 7,191 2028,5 0,000
WSCT perseverative answers 25,05 17,749 15,05 7,643 2942,5 0,001
WSCT perseverative errors 20,66 15,737 12,88 5,776 2970,5 0,001
WSCT conceptual level 16,39 13,872 28,14 10,099 1995,5 0,000
WSCT categories achieved 0,66 ,864 1,80 2,623 2091,5 0,000
WSCT to complete 1st category 41,90 26,041 23,28 19,002 2754,0 0,000
WSCT failure to maintain set 0,66 1,022 0,94 0,864 3194,5 0,004
RAVLT A1-A5 26,84 11,124 43,51 10,437 1152 0,000
RAVLT A6 5,20 2,957 9,25 3,086 1509,5 0,000
RAVLT A7 4,25 2,694 8,81 3,021 1174,5 0,000
RAVLT list B 2,96 1,428 5,34 1,523 1104 0,000
RAVLT Recognition ,71733 ,196041 ,90170 ,132401 1719 0,000
ROCFT similarity ,52 ,501 ,99 ,122 2308,5 0,000
ROCFT main elements 3,89 2,040 6,36 1,366 1406,500 0,000
TMT A 81,01 58,753 32,84 14,624 1027 0,000
TMT B 274,73 298,46 67,74 31,338 886,5 0,000
Wechsler digits forward 6,11 2,185 7,84 1,920 2422,000 0,000
Wechsler digits backward 3,70 1,638 6,07 1,645 1360 0,000
Verbal fluency 10,17 4,864 16,72 4,836 1429,5 0,000
Stroop words 77,17 18,158 94,04 12,942 1921,500 0,000
Stroop colors 55,38 16,487 73,21 13,521 1651 0,000
Stroop Interferention 29,49 12,251 44,35 10,108 1458 0,000
Stroop Coefficient 31,7587 8,06665 40,9462 6,19602 1539 0,000
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Present study is also partially consistent with the study
based on MATRICS consensus [44], in which patients
with schizophrenia exhibited greater cognitive impairment
than controls. In a cross-sectional study the authors re-
vealed that patients early in the course of schizophrenia
exhibited similar level of impairment compared to patients
with a chronic schizophrenia. The data presented here fo-
cused on differences between patients and controls, shows
that number of significant differences between inpatients
and controls increase in every single “older” subgroup
(similar age). At the same time, most cognitive functions
show a slight connection to the age and the time of dis-
ease onset whereas perseverative errors (cognitive rigidity)
seem to be associated with the difference between the
time when the disease begun and the number of years
since the first hospitalization. The longer the period of
time spent without hospitalization the greater the
cognitive rigidity shown in the study. It may be connected
with fixed deficits caused by a long period when patients
were not treated, at least in some cases.
One significant drawback of the present study is the fact
that it was cross-sectional. Thus, it is only possible to
analyze the differences between healthy individuals versus
patients with schizophrenia in the individual age groups.
Other shortcoming is linked to the fact that only inpatients
were examined, the outcomes are thus limited, because
of little likelihood of qualification to research in recov-
ered patients.
Conclusions
The conclusions of the present research indicate the possi-
bility of the occurrence of primary impairments of verbal-
learning, memory, shifting, inhibitory control and verbal
fluency, which persist in older age groups, and it is possible























18–25 U 271,00 280,50 269,00 179,50 242,00 162,00 121,50 86,00 235,50 185,00 111,00 149,00
p 0,157 0,210 0,147 0,001 0,053 0,000 0.000 0.000 0,039 0,002 0,000 0,000
26–35 U 179,00 224,00 195,50 105,50 108,50 112,00 109,50 136,00 255,50 145,00 138,00 207,00
p 0,028 0,20 0,061 0.000 0,000 0.000 0.000 0.000 0.144 0.000 0.000 0.018
36–45 U 65,00 82.50 31.00 48.00 73.00 75.00 41.00 34.00 58.50 33.00 64.50 372.00
p 0.001 0.007 0.000 0.000 0.003 0.004 0.000 0.000 0.001 0.000 0.001 0.000
46–55 U 33.50 129.50 64.50 4.00 29.50 35.50 11.00 2.50 76.000 17.00 30.50 12.00
p 0.000 0.048 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Bold print - Singificance p < 0.05
Table 8 Raw scores of individual subtests depending on age groups
Age: 18-25 Age: 26–35 Age: 36–45 Age: 46–55
M (Schi) M (Controls) M (Schi) M (Controls) M (Schi) M (Controls) M (Schi) M (Controls)
WCST total errors 33,09 28,59 33,50 28,55556 38,34 26,50 40,53 24,46
WCST pers. errors 22,21 16,36 24,81 16,94444 23,90 10,66 29,28 14,23
WCST categories ach. 0,96 2,27 0,87 1,38889 0,31 1,58 0,46 1,76
RAVLT A7 5,12 8,00 4,53 8,66667 4,28 9,0 3,06 10,25
RAVLT Recognition 0,77 0,86 0,73 0,92995 0,74 0,90 0,61 0,91
ROCFT main elements 4,25 6,04 4,37 6,80000 3,43 5,63 3,50 6,84
TMT A 72,28 30,50 62,78 33,57143 88,87 35,91 100,09 32,76
TMT B 247,53 61,45 175,21 76,57143 313,18 69,08 363,00 62,84
Digits forward 6,18 7,40 6,81 7,76190 5,75 8,36 5,68 8,23
Digits backwards 4,00 5,72 3,84 5,76190 3,68 6,36 3,28 6,92
Verbal fluency 9,37 15,54 10,90 17,15000 11,68 17,66 8,71 17,15
Stroop words 76,56 90,90 86,78 93,80 78,25 95,75 67,09 98,15
Stroop colors 54,84 71,63 62,71 71,66 54,62 75,08 49,31 76,61
Stroop Interferention 32,40 42,00 33,59 46,90 27,93 43,33 24,03 45,15
Stroop Coefficient 31,58 39,85 35,94 40,37 31,47 41,89 28,03 42,83
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that executive impairment are “less visible” in early course
of disease. Further longitudinal study should confirm if ex-
ecutive functions lower significantly in group of patients
aged 36-45.
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